INVOKANA (canagliflozin) safety and tolerability

Prescribing Information can be found under Useful Resources

Invokana^®(canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

As monotherapy when metformin is considered inappropriate due to intolerance or contraindications
In addition to other medicinal products for the treatment of diabetes

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, please refer to section 4.4, 4.5 and 5.1 of the Invokana SmPC.

When considering an SGLT2 inhibitor for your T2D patient, please view the ‘Improving Diabetes Steering Committee (IDSC) checklist’ before prescribing.

Download the Prescribing Checklist

The safety of canagliflozin was evaluated in 22,645 patients with type 2 diabetes, including 13,278 patients treated with canagliflozin and 9,367 patients treated with a comparator in 15 double-blind, controlled phase 3 and 4 clinical studies.²

Invokana AE table

Please refer to the Invokana (canagliflozin) SmPC for detailed safety information including Contraindications, Warnings and Precautions

PP-IN-UK-0239 July 2023